Preparation and characterization of neutralizing monoclonal antibodies against FMDV serotype O with synthetic peptide antigen

Hybridoma

Volumn 29, Issue 5, 2010, Pages 409-412

  Ma, Lina ^a   Liu, Yong Sheng ^a   Ding, Yao Zhong ^a   Chen, Hao Tai ^a   Zhou, Jian Hua ^a   Liu, Wen Qian ^a   Wang, Meng ^a   Zhang, Jie ^a  

^a INSTITUTE OF PLANT PROTECTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1B11; MONOCLONAL ANTIBODY 1D4; MONOCLONAL ANTIBODY 1E10; MONOCLONAL ANTIBODY 4B8; MONOCLONAL ANTIBODY 4F9; PROTEIN VP1; SYNTHETIC PEPTIDE; TISSUE POLYPEPTIDE ANTIGEN; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOOT AND MOUTH DISEASE VIRUS; HYBRIDOMA; IMMUNIZATION; MOLECULAR CLONING; MOUSE; MYELOMA CELL; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SPLEEN CELL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODY SPECIFICITY; ANTIGENS, VIRAL; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; FOOT-AND-MOUTH DISEASE VIRUS; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PEPTIDES; SEROTYPING;

FOOT-AND-MOUTH DISEASE VIRUS; MUS;

EID: 78149372160     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2010.0031     Document Type: Article

References (29)

1. Aggarwal N, and Barnett PV: Antigenic sites of foot-andmouth disease virus (FMDV): an analysis of the specificities of anti-FMDV antibodies after vaccination of naturally susceptible host species. J Gen Virol 2002;83:775-782.
2. Feliu JX, Carbonell X, and Villaverde A: Successful mimicry of a complex viral antigen by multiple peptide insertions in a carrier protein. FEBS Lett 2000;474:87-92.
3. Rana SK, and Bagchi T: Development and characterization of monoclonal antibodies against FMD virus type Asia-1 and determination of antigenic variations in the field strains. Vet Immunol Immunopathol 2008;122:241-249.
4. Xie QC, McCahon D, Crowther JR, Belsham GJ, and McCullough KC: Neutralization of foot-and-mouth disease virus can be mediated through any of at least three separate antigenic sites. J Gen Virol 1987;68:1637-1648.
5. Stave JW, Card JL, Morgan DO, and Vakharia VN: Neutralization sites of type O1 foot-and-mouth disease virus defined by monoclonal antibodies and neutralization-escape virus variants. Virology 1988;162:21-29.
6. Crowther JR, Farias S, Carpenter WC, and Samuel AR: Identification of a fifth neutralizable site on type O foot-and-mouth disease virus following characterization of single and quintuple MAb escape mutants. J Gen Virol 1993;74:1547-1553.
7. Butchaiah G, and Morgan DO: Neutralization antigenic sites on type Asia-1 foot-and-mouth disease virus defined by monoclonal antibody-resistant variants. Virus Res 1997;52: 183-194.
8. Grazioli S, Fallacara F, and Brocchi E: Mapping of neutralizing sites on FMD virus type Asia 1 and relationships with sites described in other serotypes. Report of the Session of the Research Group of the Standing Committee of the European Commission of Foot and Mouth Disease 2003;Appendix 44:277-287.
9. Thomas AAM, Woortmeijer RJ, Puijk W, and Barteling SJ: Antigenic sites on foot-and-mouth disease virus type A10. J Virol 1988;62:2782-2789.
10. Baxt B, Vakharia V, Moore DM, Franke AJ, and Morgan DO: Analysis ofneutralizing antigenic sites onthe surface of the type A12 foot-and-mouth disease virus. J Virol 1989;63:2143-2151.
11. Mateu MG, Rocha E, Vicente O, Vayreda F, Navalpotro C, Andreu D, Pedroso E, Giralt E, Enjuanes L, and Domingo E: Reactivity with monoclonal antibodies of viruses from an episode of foot-and-mouth disease. Virus Res 1987;8:261-274.
12. Verdaguer N, Fita I, Domingo E, and Mateu MG: Efficient neutralization of foot-and-mouth disease virus by monovalent antibody binding. J Virol 1997;71(12):9813-9816.
13. Strohmaier K, Franze R, and Adam KH: Location and characterization of the antigenic protein of the FMDV immunizing protein. J Gen Virol 1982;59:295-306.
14. Bittle JL, Houghten RA, Alexander H, Shinnick TM, Sutcliffe JG, Lerner RA, Rowlands DJ, and Brown F: Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature 1982;298:30-33.
15. Pfaff E, Mussgay M, Bohm HO, Shulz GE, and Schaller H: Antibodies against a preselected peptide recognize and neutralize foot-and-mouth disease virus. EMBO J 1982;1869-874.
16. Bachrach HL, Moore DM, McKercher PD, and Polatnick J: Immune and antibody responses to an isolated capsid protein of foot-and-mouth disease virus. J Immunol 1975;115: 1639-1641.
17. Bachrach HL, Morgan DO, and Moore DM: Foot-and-mouth disease virus immunogenic capsid protein VPT: N-terminal sequences and immunogenic peptides obtained by CNBr and tryptic cleavages. Intervirology 1979;12:65-72.
18. DiMarchi R, Brook G, Gale C, Cracknell V, Doel T, and Mowat N: Protection of cattle against foot-and-mouth disease by a synthetic peptide. Science 1986;232:639-641.
19. Broekhuijsen M, Van Rijn JMM, Blom AJM, Pouwels PH, Enger-Valk BE, Brown F, and Francis MJ: Fusion proteins with multiple copies of the major antigenic determinant of foot-and-mouth disease virus protect both the natural host and laboratory animals. J Gen Virol 1987;68:3137-3143.
20. Meloen RH, Puyk WC, Meijer DJA, Lankhof H, Posthumus WPA, and Schaaper MM: Antigenicity and immunogenicity of synthetic peptides of foot-and-mouth disease virus. J Gen Virol 1987;68:305-314.
21. Moran DO, and Moore DM: Protection of cattle and swine against foot-and-mouth disease (FMD) with biosynthetic peptide vaccines. Am J Vet Res 1990;51:40-45.
22. Villén J, Oliveira E, Núñ ez JI, Molina N, Sobrino F, and Andreu D: Towards a multi-site synthetic vaccine to footand- mouth disease: addition of discontinuous site peptide mimic increases the neutralization response in immunized animals. Vaccine 2004;22:3523-3529.
23. Yu H, Liu H, Qiu J, Qiao L, Zhong C, Xue T, and Wang M: Preparation and characterization of a novel monoclonal antibody specific to human NOB1 protein. Hybridoma 2008;27:187-190.
24. Cao J: Preparation and characterization of a novel monoclonal antibody specific to peptide VEHVVADAGAFLRH. Hybridoma 2009;28:59-62.
25. Li X, Mao C, Ma S, Wang X, Sun Z, Yi Y, Guo M, and Shen X: Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides. Biochem Biophys Res Commun 2009;390:1126-1128.
26. Kohler G, and Milstein C: Continuous culture of fused cells secreting antibody of predefined sensitivity. Nature 1975; 256:495-497.
27. Friguet B, Djavadi-Ohaniance L, Pages J, Bussard A, and Goldberg M: A convenient enzyme-linked immunosorbent assay for testing whether monoclonal antibodies recognize the same antigenic site. Application to hybridomas specific for the beta 2-subunit of Escherichia coli tryptophan synthase. J Immunol Methods 1983;60:351-358.
28. Kaaden OR, Adam KH, and Strohmaier K: Induction of neutralizing antibodies and immunity in vaccinated guinea pigs by cyanogen bromide-peptides of VP3 foot-and-mouth disease virus. J Gen Virol 1977;34:397-400.
29. Karber G: Beitrag zur kollektitoven behandlung pharmakologischer Reihenversuche. Archiv fur experimentelle pathologie und pharmakologie. 1931;162:480.